Edition:
United States

UMN Pharma Inc (4585.T)

4585.T on Tokyo Stock Exchange

464JPY
--
Change (% chg)

-- (--)
Prev Close
¥464
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
379,212
52-wk High
¥2,755
52-wk Low
¥461

Summary

Name Age Since Current Position

Tatsuyoshi Hirano

57 2013 Chairman of the Board, President, President of Subsidiary, Representative Director

Hiroyuki Hashimoto

48 2012 Director of Finance, Director

Fumihisa Nakata

48 2011 Director of Clinical Development, Director

Tsutomu Narikiyo

56 2012 Independent Director

Biographies

Name Description

Tatsuyoshi Hirano

Mr. Tatsuyoshi Hirano has been serving as Chairman of the Board, President and Representative Director in UMN Pharma Inc., as well as President and Representative Director of a subsidiary, UNIGEN Inc., since August 2013. Prior to that, he served as President and Representative Director of the Company, as well as Director of UNIGEN Inc. He joined the Company in January 2009 and served as Director of Finance. He used to work for other Japan-based companies, including Shin-Etsu Chemical Co., Ltd. He received his Bachelor's degree in Social Sciences from Hitotsubashi University in 1984 and his Master's degree in Economics from Johns Hopkins University.

Hiroyuki Hashimoto

Mr. Hiroyuki Hashimoto has been serving as Director of Finance and Director of UMN Pharma Inc. since March 2012. He is also serving as Director in a subsidiary. He joined the Company and previously served as Manager of Business Planning Unit in the Company. He used to work for other three companies.

Fumihisa Nakata

Mr. Fumihisa Nakata has been serving as Director of Clinical Development and Director in UMN Pharma Inc. since August 2011. He is also serving as director in UNIGEN Inc., a subsidiary of the Company. He joined the Company in March 2010 and previously served as Director of Pharmaceutical Affairs in the Company. He used to work for other two Japan-based companies.

Tsutomu Narikiyo

Mr. Tsutomu Narikiyo has been serving as Independent Director in UMN Pharma Inc. since March 2012. He is also serving as Director in a subsidiary, as well as working for IHI Corporation.

Basic Compensation

Options Compensation